DA-020 is named as an intervention in 2 current clinical trials in our Italy and Brazil registers. 1 is recruiting patients now. The most common phase is Phase EARLY_PHASE1. The lead sponsor is Applied Biology, Inc. The most-studied condition is Chemotherapy Induced Alopecia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
NCT07397325 · ClinicalTrials.gov ↗ · Chemotherapy Induced Alopecia, Chemotherapy Side Effects
|
Phase 1/2 | Recruiting | Applied Biology, Inc | Italy, Brazil |
|
Pharmacokinetic Study of DA-020
NCT07402330 · ClinicalTrials.gov ↗ · Chemotherapy Induced Alopecia, Chemotherapy Side Effects
|
Phase EARLY_PHASE1 | Not yet open | Applied Biology, Inc | Italy, Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Applied Biology, Inc | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Italy | 2 | 1 |
| Clinical trials in Brazil | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Italy and Brazil registers name DA-020 as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Italy and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Applied Biology, Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how DA-020 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how DA-020 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists DA-020 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.